

# News Release

## News Release

CONTACT: Andrew Bright  
+ 1 (484) 530 3922  
[andrew.bright@oncura.com](mailto:andrew.bright@oncura.com)  
[www.oncura.com](http://www.oncura.com)

### **Dr Aaron Katz of Columbia Presbyterian Presents 10-Year Prostate Cryotherapy Data at the American Urological Association (AUA) Annual Meeting in San Antonio**

Philadelphia (May 25, 2005) – ONCURA, a global leader in the minimally invasive management of prostate cancer congratulates Dr. Aaron Katz (Associate Professor of Clinical Urology, Columbia Presbyterian, New York) on the presentation of his group's 10-year experience with prostate cryotherapy in patients who've relapsed after previous radiation therapy. The presentation at this year's American Urological Association meeting in San Antonio represents a significant body of clinical data, and one that's been generated by a world renowned center of excellence.

"Dr Katz's long-term data is evidence that an option for cure is still available for patients previously treated but have unfortunately seen their disease return," said James McGlone, President and CEO of ONCURA. He added, "Dr Katz has always been an innovator in prostate cryotherapy and his data now bring hope to men who've been searching for an option for their recurring prostate cancer."

Dr Katz is a pioneer in the use of cryotherapy for the treatment of prostate cancer and has over 50 peer-reviewed publications describing outstanding cure rates in respected journals such as the Journal of Urology, Molecular Urology, British Journal of Urology, Cancer, and Cancer Research. Dr Katz is noted as an expert for his experience in using cryotherapy as an option for patients who have previously received radiation therapy but have unfortunately seen their cancer return.

"The patients in this study were treated with a series of cryotherapy systems, representing the evolution of this technology since the early 1990's" said Dr Katz. He added, "Since September of 2004 I've been using ONCURA's minimally invasive 17 gauge IceRod™ needles; and as our data show have seen further improvements in both disease control and side effects."

ONCURA's patented 17 gauge needles represent the most minimally invasive option available for prostate cryotherapy. ONCURA 's focus is on the effective delivery of therapy, while minimizing side effects wherever possible. The 17 gauge family of cryoneedles allows physicians to select a minimally invasive option that best suits their patient's clinical situation, as well as matching their own experience and expertise.

Dr. Katz is a member of the American Urological Association, the Society of Urologic Cryosurgeons, the Society of University Urologists and the Southwest Oncology Group. Over the course of his career, Dr. Katz has won numerous awards and grants, including one from the NIH to study the molecular staging of prostate cancer, as well as one from CaPCure for the investigation of an antibody to prevent the recurrence of prostate cancer. Dr Katz can be contacted via email at [aek4@columbia.edu](mailto:aek4@columbia.edu).

ONCURA was created through the merger of Amersham plc's brachytherapy business and Galil Medical Ltd's urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURA's International business is operated from its UK subsidiary. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.